...
首页> 外文期刊>Clinical & translational oncology : >Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics
【24h】

Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics

机译:Germline BRCA测试正在从癌症风险评估转变为针对癌症治疗剂的预测性生物标志物

获取原文
获取原文并翻译 | 示例

摘要

Originally, BRCA testing was used for risk assessment and prevention strategies for breast and ovarian cancer. Nowadays, BRCA status may influence therapeutic decision making at cancer diagnosis. Our objective was to analyze whether the medical advances have changed the burden and pattern of referral, and the pathogenic mutation detection rate.
机译:最初,BRCA测试用于乳腺癌和卵巢癌的风险评估和预防策略。如今,BRCA的状态可能会影响癌症诊断中的治疗决策。我们的目的是分析医学的进步是否改变了转诊的负担和方式以及病原体突变的检出率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号